May 27, 2026- Abbott announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC. Both tests are used at a three-year interval.
Cologuard and Cologuard Plus are preferred, U.S. Preventive Services Task Force-recommended noninvasive screening tests designed to detect CRC early – when it is most treatable – and identify precancerous lesions that can be removed during follow-up colonoscopy. Cologuard Plus detects 95% of colorectal cancers at 94% specificity age-weighted to the U.S. screening population, which is expected to minimize unnecessary follow-up colonoscopies and maximize confidence in results.
Both tests are backed by Abbott’s well-established patient navigation support and commercial infrastructure to ensure scale, reliability, and seamless patient and provider experiences. Further, both tests are included in colorectal cancer screening quality measures, such as HEDIS and Stars, which support payer and provider quality incentives.
Continue Reading from Abbott here.